Swan Capital’s Roivant Sciences ROIV Stock Holding History

Swan Capital’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-75	Closed	-$757	–	500
2025 Q1	$757	Sell	75 -15	-17%	-$162	﹤0.01%	305
2024 Q4	$1.06K	Buy	+90	New	+$1.06K	﹤0.01%	278

Other funds holding ROIV

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PSC

Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Swan Capital's ROIV Position: Q2 2025 in Review

Swan Capital sold out of Roivant Sciences (ROIV) in Q2 2025, closing a stake of 75 shares — an estimated $757 sold.

Swan Capital first reported a position in ROIV in Q4 2024 and held it in 2 quarters. The position peaked at $1.06K in Q4 2024. 337 funds tracked by Wall St. Rank hold ROIV as of Q2 2025.

Swan Capital reported no remaining Roivant Sciences position as of Q2 2025 after selling out during the quarter.
Swan Capital sold 75 Roivant Sciences shares in Q2 2025, an estimated $757.
Swan Capital first reported a position in Roivant Sciences in Q4 2024 and held it in 2 quarters.
Swan Capital's Roivant Sciences position peaked at $1.06K in Q4 2024.
337 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2025.

Based on Swan Capital's 13F filing for Q2 2025, filed 14 Aug 2025.